Download 1427967058PR Aptar Pharma Twister Sine Promod 040215LV

PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE
PRESCRIPTION
Aptar Pharma Twister ® Chosen for Asthma Therapy
Louveciennes, France - April 2, 2015 - Aptar Pharma, a global solution provider of
innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare
and pharma products has partnered with Shanghai Sine Promod Pharmaceutical
Co., Ltd. to develop and launch its new Budesonide DPI (Dry Powder Inhaler), which
uses Aptar Pharma’s novel, user-friendly and cost-effective Twister® Dry Powder Inhaler.
The first drug product marketed with Twister®
Budesonide DPI is designed for maintenance therapy in the treatment
of asthma. Budesonide DPI is one of the first drug products
manufactured locally and marketed in China. This cost-effective drug
product incorporates Aptar Pharma’s Twister® technology. Budesonide
DPI contains an inhaled corticosteroid for the treatment of asthma in
adults and children age six and over. The product is marketed in two
versions, one version containing 30 capsules and the other, 60 capsules.
Each capsule consists of 200µg of budesonide blended with lactose
monohydrate as the carrier.
Constant growth in the asthma treatment market
The World Health Organization (WHO) estimates that approximately 235 million people worldwide suffer from asthma,
with over 30 million in China alone. Due mainly to population growth in Chinese cities, increased air pollution is becoming
a major cause of respiratory diseases. The Chinese Asthma and COPD market is growing rapidly, with a CAGR of 22.5%
over the past five years.
Key benefits of Aptar Pharma’s Twister®
Twister® is a new capsule-based DPI, designed and developed by a multidisciplinary technical team based at Aptar Pharma’s Centre of Excellence in
Le Vaudreuil, France to specifically address unmet medical needs in fast-growing
markets.
Twister® has a simple and robust design with few components, making it costeffective for asthma and COPD treatments, and has been tested and validated with
a number of different dry powder drug formulations.
Twister® is designed to be patient-friendly and easy to use, allowing patients easy
access to their medication in three simple steps: insert, twist and inhale. To help
improve patient compliance with the prescribed treatment, Twister® is transparent,
allowing the capsule and powder to be seen in the device as they are administered.
In addition to these visual cues, the patient is also guided by audible feedback
during inhalation.
“Shanghai Sine Promod Pharmaceutical Co., Ltd is one of Aptar Pharma’s key customers in China. We are particularly
proud to have supported their Budesonide DPI program through the development and commercialization of Twister®,
manufactured locally in our Suzhou facility. This is a very important milestone for Aptar Pharma China,” stated Mrs Yan
Jiang, Vice President Northeast Asia for Aptar Pharma.
1/2
PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE
PRESCRIPTION
About Aptar Pharma
Aptar Pharma is part of the AptarGroup, Inc. family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage. We
create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies
around the world. We provide our customers with a wide range of delivery technologies and analytical services backed by decades
of proven expertise.
AptarGroup, Inc. (NYSE: ATR) is headquartered in Crystal Lake, Illinois, United States, with manufacturing facilities in North America,
Europe, Asia and South America.
For more information, visit www.aptar.com/pharma
About Shanghai Sine Promod Pharmaceutical Co., Ltd
Shanghai Sine Promod Pharmaceutical Co., Ltd., was established in 1994, and specializes in cardiovascular, anti-inflammatory and
respiratory drugs. A total of 30 products have been launched in the Chinese market, covering 28 provinces and municipalities.
Press Contacts
Elisa Eschylle, Events and Press relations manager
Tel.: +33 (0)1 39 17 20 41 - E-mail: [email protected]
Marion Baschet Vernet, Press attaché
Tel.: +33 (0)6 22 17 08 96 - E-mail: [email protected]
Delivering solutions, shaping the future.
2/2